[On the local efficacy of ciclopiroxolamine in onychomycoses (author's transl)].
An open, multicenter clinical trial of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, 2-aminoethanol salt (ciclopiroxolamine, Cic, Hoe 296, Batrafen) was performed in 150 patients with 246 nails afflicted by mycotic infection. Dermatophytes were observed in 96% of the initial cultures. A combination of 1% Cic solution and cream was applied, and a very strict nail toilet was performed. The mean duration of study was 12.7 +/- 5.6 weeks, followed by a 6 week follow-up period on the average. The share of pathologically changed nails of 35 +/- 16% was reduced to 8 +/- 10% of nail plate. In a total of 96% of patients, some of whom had only been treated for a brief period, a measurable improvement was observed, and 57% of the patients were free from signs of infection. Signs of intolerance or definite relapses were not observed.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D000077768:Ciclopirox; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014009:Onychomycosis / Q000188:drug therapy*; D011728:Pyridones / Q000627:therapeutic use*
D000935:Antifungal Agents; D011728:Pyridones; D000077768:Ciclopirox
Zur Lokalwirksamkeit von Ciclopiroxolamin bei Nagelmykosen.